Stomach Diseases
15
0
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.7%
1 terminated out of 15 trials
88.9%
+2.4% vs benchmark
20%
3 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (15)
Diet Intervention on Obesity Related Complication
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms
Magnetically Controlled Capsule Endoscopy in Visualization of the UGI and Small Intestine
Diagnosis of Gastric Lesions From Exhaled Breath and Saliva
Repetitive Position Change Improves Gastric Cleanliness for MCE
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Gastric Preparation of Magnetic-controlled Capsule Endoscopy
Transit Time and Bacterial Overgrowth Using SmartPill Capsule
Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy
Drop in Gastroscopy - Experience After 9 Months
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time